NovoCure (NVCR) FCF Margin Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 38.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 30.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 943.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 96.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -2,196.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -20.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 2,679.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -461.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 417.00 |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 795.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 795.00 |
| Dec 31, 2025 | -524.00 |
| Sep 30, 2025 | -384.00 |
| Jun 30, 2025 | -2,175.00 |
| Mar 31, 2025 | -2,347.00 |
| Dec 31, 2024 | -778.00 |
| Sep 30, 2024 | -1,599.00 |
| Jun 30, 2024 | -2,640.00 |
| Mar 31, 2024 | -4,155.00 |
| Dec 31, 2023 | -4,913.00 |
| Sep 30, 2023 | -4,211.00 |
| Jun 30, 2023 | -3,167.00 |
| Mar 31, 2023 | -1,754.00 |
| Dec 31, 2022 | -1,183.00 |
| Sep 30, 2022 | -49.00 |
| Jun 30, 2022 | 57.00 |
| Mar 31, 2022 | 267.00 |
| Dec 31, 2021 | -2,146.00 |
| Sep 30, 2021 | 918.00 |
| Jun 30, 2021 | 3,121.00 |
| Mar 31, 2021 | 4,393.00 |
| Dec 31, 2020 | 4,864.00 |
| Sep 30, 2020 | 1,725.00 |
| Jun 30, 2020 | 2,442.00 |
| Mar 31, 2020 | 7,897.00 |
| Dec 31, 2019 | 5,136.00 |
| Sep 30, 2019 | 17,571.00 |
| Jun 30, 2019 | 18,478.00 |
| Mar 31, 2019 | 23,594.00 |
| Dec 31, 2018 | 24,101.00 |
| Sep 30, 2018 | 26,689.00 |
| Jun 30, 2018 | 36,850.00 |
| Mar 31, 2018 | 52,459.00 |
| Dec 31, 2017 | 45,865.00 |